Literature DB >> 20876390

CT colonography for combined colonic and extracolonic surveillance after curative resection of colorectal cancer.

Hye Jin Kim1, Seong Ho Park, Perry J Pickhardt, Sang Nam Yoon, Seung Soo Lee, Judy Yee, David H Kim, Ah Young Kim, Jin Cheon Kim, Chang Sik Yu, Hyun Kwon Ha.   

Abstract

PURPOSE: To determine the accuracy of contrast material-enhanced computed tomographic (CT) colonography for postoperative surveillance in colorectal cancer patients without clinical or laboratory evidence of disease recurrence.
MATERIALS AND METHODS: The Institutional Review Board approved this HIPAA-compliant study and waived informed consent. Between January 2006 and December 2007, 742 consecutive patients without clinical or laboratory evidence of recurrence following curative-intent colorectal cancer surgery underwent contrast-enhanced CT colonography. Of these, 548 patients who had subsequent colonoscopy and pathologic confirmation of colonic lesions (reference standard) were included in the colonic analysis. All 742 patients were included in the extracolonic analysis. Sensitivity and specificity of CT colonography for nonanastomotic colonic lesions at least 6 mm in size and anastomotic lesions of any size, including performance according to lesion histologic type, were determined. Diagnostic yields of contrast-enhanced CT colonography for colonic cancers and for extracolonic recurrences were obtained.
RESULTS: CT colonography depicted all six metachronous cancers and one anastomotic recurrence within the colon in six patients (0.8%; 95% confidence interval [CI]: 0.3%, 1.8%]), for per-patient and per-lesion sensitivities of 100% (95% CIs: 64.3%, 100% and 67.8%, 100%, respectively). All cancer lesions within the colon were amenable to additional curative treatment. CT colonography per-patient and per-lesion sensitivity was 81.8% (95% CI: 60.9%, 93.3%) and 80.8% (95% CI: 64.3%, 97.2%), respectively, for advanced neoplasia and 80.0% (95% CI: 68.6%, 88.1%) and 78.5% (95% CI: 68.3%, 88.7%), respectively, for all adenomatous lesions. Negative predictive values for adenocarcinoma, advanced neoplasia, and all adenomatous lesions were 100%, 99.1%, and 97.0%, respectively. CT colonography specificity was 93.1% (95% CI: 90.4%, 95.2%). Contrast-enhanced CT colonography enabled detection of extracolonic recurrences in an additional 11 patients (1.5%; 95% CI: 0.8%, 2.7%).
CONCLUSION: Contrast-enhanced CT colonography is an accurate and practical surveillance tool following colorectal cancer surgery in patients without clinical or laboratory evidence of recurrence, allowing for simultaneous less-invasive evaluation of both colon and extracolonic organs. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.10100385/-/DC1. © RSNA, 2010

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876390     DOI: 10.1148/radiol.10100385

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  19 in total

1.  The essence of the Japan Radiological Society/Japanese College of Radiology Imaging Guideline.

Authors:  Yasuyuki Yamashita; Sadayuki Murayama; Masahiro Okada; Yoshiyuki Watanabe; Masako Kataoka; Yasushi Kaji; Keiko Imamura; Yasuo Takehara; Hiromitsu Hayashi; Kazuko Ohno; Kazuo Awai; Toshinori Hirai; Kazuyuki Kojima; Shuji Sakai; Naofumi Matsunaga; Takamichi Murakami; Kengo Yoshimitsu; Toshifumi Gabata; Kenji Matsuzaki; Eriko Tohno; Yasuhiro Kawahara; Takeo Nakayama; Shuichi Monzawa; Satoru Takahashi
Journal:  Jpn J Radiol       Date:  2016-01       Impact factor: 2.374

Review 2.  Role of CT colonography in symptomatic assessment, surveillance and screening.

Authors:  L Maximilian Almond; Douglas M Bowley; Sharad S Karandikar; Shuvro H Roy-Choudhury
Journal:  Int J Colorectal Dis       Date:  2011-03-19       Impact factor: 2.571

3.  Dual-energy CT characteristics of colon and rectal cancer allows differentiation from stool by dual-source CT.

Authors:  İlknur Özdeniz; İlkay S İdilman; Seyfettin Köklü; Erhan Hamaloğlu; Mustafa Özmen; Deniz Akata; Muşturay Karçaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2017 Jul-Aug       Impact factor: 2.630

4.  Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery.

Authors:  David S Weinberg; Perry J Pickhardt; David H Bruining; Kristin Edwards; Joel G Fletcher; Marc J Gollub; Eileen M Keenan; Sonia S Kupfer; Tianyu Li; Sam J Lubner; Arnold J Markowitz; Eric A Ross
Journal:  Gastroenterology       Date:  2017-11-22       Impact factor: 22.682

5.  CT Colonography to exclude colorectal cancer in symptomatic patients.

Authors:  Sarit Badiani; Silvia Tomas Hernandez; Sharad Karandikar; Shuvro Roy-Choudhury
Journal:  Eur Radiol       Date:  2011-05-22       Impact factor: 5.315

6.  Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Charles J Kahi; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas J Robertson; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-02-12       Impact factor: 10.864

Review 7.  CT colonography in the diagnosis and management of colorectal cancer: emphasis on pre- and post-surgical evaluation.

Authors:  Nurhee Hong; Seong Ho Park
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 8.  Computed tomography colonography in 2014: an update on technique and indications.

Authors:  Andrea Laghi
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Computed tomography colonography: emerging evidence to further support clinical effectiveness.

Authors:  Perry J Pickhardt
Journal:  Curr Opin Gastroenterol       Date:  2013-01       Impact factor: 3.287

Review 10.  CT colonography for surveillance of patients with colorectal cancer: Systematic review and meta-analysis of diagnostic efficacy.

Authors:  François Porté; Mallikarjuna Uppara; George Malietzis; Omar Faiz; Steve Halligan; Thanos Athanasiou; David Burling
Journal:  Eur Radiol       Date:  2016-03-18       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.